Current perceptions of cardiovascular gene therapy.

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Biotechnology

Background:

• Perceptions of gene therapy for cardiovascular disease differ among scientists, healthcare professionals, and the public.
• Understanding these varying perspectives is crucial for the successful implementation of gene therapy.

Purpose of the Study:

• To analyze the diverse expectations and perceived risks associated with gene therapy in cardiovascular disease treatment.
• To identify factors influencing the acceptance and adoption of gene therapy by different stakeholder groups.

Main Methods:

• Review of current scientific understanding and clinical trial requirements for gene therapy.
• Analysis of perspectives from gene therapists, interventional cardiologists, general physicians, nurses, and patients.
• Consideration of regulatory, reimbursement, and media influences.

Main Results:

• Gene therapists emphasize vector selection, gene targeting, and physiological response characterization.
• Interventional cardiologists prioritize clinical efficacy and safety data.
• Physicians' attitudes are influenced by clinical trial activity and media, with a need for clear referral guidelines.
• Nurses require additional genetics education, and patient acceptance hinges on addressing misconceptions.

Conclusions:

• Successful gene therapy adoption for cardiovascular disease requires aligning scientific rigor with the practical needs and perceptions of all stakeholders.
• Addressing knowledge gaps, ensuring robust safety and efficacy data, and clear communication are essential for widespread acceptance.